Results 101 to 110 of about 49,034 (266)

Current Knowledge of Immune Checkpoint Inhibitor‐Induced Thrombocytopenia: Epidemiology, Mechanisms, and Management

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Immune checkpoint inhibitors (ICIs) have been widely adopted in the treatment of malignant tumors, and their durable antitumor effects have revolutionized cancer therapy. Immune checkpoint inhibitor‐induced thrombocytopenia (ICIIT) represents a rare but potentially severe or even fatal hematologic toxicity associated with immunotherapy ...
Youran Dai, Wenhui Yang, Zexing Sun, Linfeng Wu, Keding Shao, Dijiong Wu   +5 more
wiley   +1 more source

Microangiopatía trombótica en paciente con síndrome antisintetasa : a propósito de un caso [PDF]

, 2015
Las microangiopatías trombóticas se caracterizan por presentar anemia hemolítica microangiopática asociada a plaquetopenia, fallo renal y lesión neurológica. El Síndrome anti-sintetasa es una entidad poco frecuente perteneciente al grupo de las miopatías
Carena, José Alberto, Gómez Centurión, Santiago, Ruiz, Pedro, Salomón, Susana Elsa, Vera, Carolina   +4 more
core  

Plasma von Willebrand factor levels predict in-hospital survival in patients with acute-on-chronic liver failure [PDF]

, 2016
BACKGROUND AND AIMS: Circulating levels of von Willebrand factor (vWF) predict mortality in patients with cirrhosis. We hypothesized that systemic inflammation in acute-on-chronic liver failure (ACLF) will stimulate endothelium, increase vWF levels, and ...
Amirtharaj, GJ, Balasubramanian, KA, Eapen, CE, Elias, E, Goel, A, Mackie, I, Prasanna, KS, Ramachandran, A, Sajith, KG, Zachariah, U   +9 more
core   +1 more source

Probable Catastrophic Antiphospholipid Syndrome Overlapping Hematological Abnormalities: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT A young South Asian woman presented four weeks post‐miscarriage with fever, jaundice, edema, headache, neurological deficits, anemia, thrombocytopenia, proteinuria, hematuria, splenic infarct, and cerebral venous sinus thrombosis. Positive beta‐2 glycoprotein IgG and lupus anticoagulant supported probable CAPS.
Faseeh Ullah, Maryam Tariq, Marwa Farzand, Irha Riaz, Rizwan Rasol Khan, Kritick Bhandari   +5 more
wiley   +1 more source

Caplacizumab in the Treatment of Patients with Recurrent Thrombotic Thrombocytopenic Purpura (TTP) [PDF]

Documenta Haematologica
We report two cases of recurrent thrombotic thrombocytopenic purpura, both patients without significant personal pathological antecedents, in which the evolution was favorable following the association of Caplacizumab with the classic treatment with ...
Mihaela-Sabrina HERDEA, Adela-Sara IONESCU, Oana PATRINOIU, Mihaela ANDREESCU   +3 more
doaj   +1 more source

Reversible cerebral vasoconstriction syndrome: A narrative review

Headache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1162-1180, May 2026.
Abstract Objectives/Background This review summarizes current insights into Reversible cerebral vasoconstriction syndrome (RCVS) diagnosis, management, and outcomes. RCVS is a cerebrovascular disorder characterized by recurrent thunderclap headaches and transient segmental vasoconstriction of cerebral arteries, typically resolving within 3 months ...
Ícaro Araújo de Sousa, Abner da Silva Machado, Arthur de Oliveira Veras, Thiago Oscar Goulart, Sarah Galassi Tatsuta, Trajano Aguiar Pires Gonçalves, Eva Rocha, Octávio Marques Pontes‐Neto   +7 more
wiley   +1 more source

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study

Journal of Thrombosis and Haemostasis, 2019
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life‐threatening autoimmune thrombotic microangiopathy. Caplacizumab, an anti‐von Willebrand Factor Nanobody®, is effective for treating aTTP episodes and is well tolerated.
P. Knoebl, S. Cataland, F. Peyvandi, P. Coppo, M. Scully, J. K. Kremer Hovinga, A. Metjian, J. de la Rubia, K. Pavenski, Jessica Minkue Mi Edou, H. de Winter, F. Callewaert   +11 more
semanticscholar   +1 more source

Biopharmaceuticals for Cancer Treatment: An Update

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath, Yousuf Alam, Afsana Mustak Mim, Maksuda Akter, Mohammad Abbas Gani, Khondaker Muhammad Khairul Alam, Md. Nur Alam   +6 more
wiley   +1 more source

Eculizumab for Gemcitabine-Induced Hemolytic Uremic Syndrome: A Novel Therapy for an Emerging Condition [PDF]

, 2015
Introduction Atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA), is a disease characterized by hemolytic anemia, thrombocytopenia, and renal impairment. Gemcitabine, a commonly used chemotherapy, is emerging as a cause of aHUS.
Karkowsky, MD, Raphael, Parikh, MD, Kinjal   +1 more
core   +2 more sources

Concomitant Immune‐Mediated Thrombotic Thrombocytopenic Purpura and Evans Syndrome With Multiple Cerebral Infarctions in an Elderly Patient

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT We report a rare case of concomitant immune thrombotic thrombocytopenic purpura (iTTP) and Evans syndrome, complicated by multiple cerebral infarctions. The patient presented with severe thrombocytopenia and hemolytic anemia, as well as a positive direct Coombs test. The initial diagnosis was Evans syndrome.
Shinichi Ogawa, Yangsu Kim, Takayoshi Ito   +2 more
wiley   +1 more source